Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

ClinicalTrials.gov ID: NCT00808288

Public ClinicalTrials.gov record NCT00808288. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.

Study identification

NCT ID
NCT00808288
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
405 participants

Conditions and interventions

Interventions

  • PF- 00610355 Drug
  • Placebo Drug
  • Salmeterol Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2010
Primary completion
Nov 30, 2010
Completion
Nov 30, 2010
Last update posted
Feb 5, 2019

2010

United States locations

U.S. sites
30
U.S. states
16
U.S. cities
25
Facility City State ZIP Site status
Pfizer Investigational Site Fairhope Alabama 36532
Pfizer Investigational Site San Diego California 92120
Pfizer Investigational Site Spring Valley California 91978
Pfizer Investigational Site Wheat Ridge Colorado 80033
Pfizer Investigational Site Daytona Beach Florida 32114
Pfizer Investigational Site Ormond Beach Florida 32174
Pfizer Investigational Site Tampa Florida 33613
Pfizer Investigational Site Trinity Florida 34655
Pfizer Investigational Site Austell Georgia 30106
Pfizer Investigational Site Overland Park Kansas 66211
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Fridley Minnesota 55432
Pfizer Investigational Site Minneapolis Minnesota 55407
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Charlotte North Carolina 28207
Pfizer Investigational Site Cincinnati Ohio 45227
Pfizer Investigational Site Cincinnati Ohio 45231
Pfizer Investigational Site Cincinnati Ohio 45242
Pfizer Investigational Site Cincinnati Ohio 45245
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Lincoln Rhode Island 02865
Pfizer Investigational Site Pawtucket Rhode Island 02860
Pfizer Investigational Site Charleston South Carolina 29407
Pfizer Investigational Site Charleston South Carolina 29414
Pfizer Investigational Site Columbia South Carolina 29204
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site San Antonio Texas 78212
Pfizer Investigational Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00808288, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2019 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00808288 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →